

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

REGENERON PHARMACEUTICALS, INC.,
Petitioner,

v.

NOVARTIS PHARMA AG,
NOVARTIS TECHNOLOGY LLC,
NOVARTIS PHARMACEUTICALS CORPORATION,
Patent Owner.

Case IPR2021-00816
U.S. Patent No. 9,220,631 B2

JOINT MOTION TO EXPUNGE

Pursuant to the Board’s July 13, 2022 email, Patent Owners Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corporation (collectively, “Novartis”) and Petitioner Regeneron Pharmaceuticals, Inc. (“Regeneron”) (Regeneron and Novartis, collectively, “Parties”) respectfully request that the Board expunge the exhibits listed below:

Ex. 1101	Declaration of Dr. Gregory Sawyer – Filed Under Seal
Ex. 1110	Persson, et. al., <i>Elastic contact mechanics: Percolation of the contact area and fluid squeeze-out</i> , Eur. Phys. J. E. (2012)
Ex. 1112	NOVITC(CH)00137958 – Novartis Confidential Internal Memorandum – Filed Under Seal
Ex. 1113	NOVITC(CH)00143346 – Novartis Confidential Internal Memorandum – Filed Under Seal
Ex. 1114	NOVITC(CH)00258369 – Novartis Confidential Internal Presentation – Filed Under Seal
Ex. 1116	NOVITC(CH)00195649 – Vetter Confidential Memorandum – Filed Under Seal
Ex. 1117	NOVITC(CH)00145642 – Novartis Confidential Meeting Minutes – Filed Under Seal
Ex. 1118	NOVITC(CH)00144912 – Novartis Confidential Meeting Minutes – Filed Under Seal
Ex. 1119	NOVITC(CH)00205699 – Vetter Confidential Presentation – Filed Under Seal
Ex. 1120	NOVITC(CH)00184035 – Vetter Confidential Memorandum – Filed Under Seal
Ex. 1121	NOVITC(CH)00198709 – Vetter Confidential Presentation – Filed Under Seal
Ex. 1122	NOVITC(CH)00867567 – Vetter Confidential Memorandum – Filed Under Seal
Ex. 1123	NOVITC(CH)00150140 – Vetter Confidential Emails – Filed Under Seal
Ex. 1124	NOVITC(CH)00337493 – Vetter Confidential Presentation – Filed Under Seal
Ex. 1125	NOVITC(CH)00352054 – Vetter Confidential Emails – Filed Under Seal

Ex. 1126	VETTER_00001432 – Vetter Confidential Presentation – Filed Under Seal
Ex. 1127	NOVITC(CH)00170626 – Vetter Confidential Memorandum – Filed Under Seal
Ex. 1128	NOVITC(CH)00170434 – Vetter Confidential Letter – Filed Under Seal
Ex. 1129	REGITC01116474 – DE 20 2012 011 016.0
Ex. 1130	NOVITC(CH)00170689 – Novartis Confidential Agreement – Filed Under Seal
Ex. 1131	NOVITC(CH)00217299 – Novartis Confidential Presentation – Filed Under Seal
Ex. 1132	NOVITC(CH)00311660 – Novartis Confidential Report – Filed Under Seal
Ex. 1133	NOVITC(CH)00133717 – Novartis Confidential Report – Filed Under Seal
Ex. 1134	NOVITC(CH)03375527 – Novartis Confidential Presentation – Filed Under Seal
Ex. 1135	NOVITC(CH)03530811 – Novartis Confidential Presentation – Filed Under Seal
Ex. 1136	NOVITC(CH)03540210 – Novartis Confidential Presentation – Filed Under Seal
Ex. 1160	Picci ITC Deposition Transcript (12/16/2020) – Filed Under Seal
Ex. 1163	REGITC00138524 – Requirements on pre-fillable glass syringes
Ex. 1164	<i>Optical in Situ Micro Tribometer for Analysis of Real Contact Area for Contact Mechanics, Adhesion, and Sliding Experiments</i> , B. A. Krick, J. R. Vail, B. N. J. Persson, and W. G. Sawyer, Tribology Letters 45 (2012) 185-194
Ex. 1165	<i>Plasmonic Diagnostics for Tribology: In Situ Observations using Surface Plasmon Resonance in Combination with Surface-Enhanced Raman Spectroscopy</i> , B. A. Krick, D. H. Hahn, and W. G. Sawyer, Tribology Letters, 49 (2013) 95-102.
Ex. 1166	<i>Accessing Inaccessible Interfaces: In Situ Approaches to Materials Tribology</i> , W. G. Sawyer & K. J. Wahl, Guest Editors MRS Bulletin 33 (2008) 1145-1189
Ex. 1167	VETTER_10013300_EN (Certified Translation) – Vetter Confidential Emails – Filed Under Seal
Ex. 1169	Lorenz, et al., <i>Static or breakloose friction for lubricated contacts: the role of surface roughness and dewetting</i> , J. Phys. Condens. Matter 25 (2013)

Ex. 1181	“Beovu (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) age-related macular degeneration,” Yahoo Finance, December 16, 2021, available at https://finance.yahoo.com/news/beovu-brolucizumab-injectionnow-publicly-120000109.html?guccounter=1
Ex. 2208	Declaration of Kimberly Cameron, Ph.D. In Support of Novartis’s Motion to Amend [Filed Under Seal]
Ex. 2210	Curriculum Vitae of Dr. Kimberly Cameron
Ex. 2211	Curriculum Vitae of Dr. Jeremy Wolfe
Ex. 2212	Eylea Label 2021
Ex. 2213	Lucentis Label 2017
Ex. 2214	Rahul Chaturvedi et al., Real World Trends in Intravitreal Injection Practices Among American Retina Specialists, <i>Ophthalmology Retina</i> (Aug. 2019), 3(8):656-662
Ex. 2218	Francesco Cilurzo et al., <i>Injectability Evaluation: An Open Issue</i> , <i>AAPS PharmSciTech</i> (June 2011), 12(2):604-9
Ex. 2222	Summary of EU Product Characteristics, Lucentis PFS (E.U.)
Ex. 2229	Nitin Rathore et al., <i>Variability in Syringe Components and its Impact on Functionality of Delivery Systems</i> , <i>PDA J. Pharm. Sci. Tech.</i> (201), 65(5):468-480
Ex. 2230	European Medicines Agency, ICH Topic Q 5 C, “Quality of Biotechnological Products,” CPMP/ICH/138/95 (July 1996)

Dated: August 12, 2022

By: Elizabeth J. Holland/
Elizabeth J. Holland (Reg. No. 47,657)
Lead Counsel for Patent Owners
Allen & Overy LLP
1221 Avenue of the Americas
New York, NY 10020
Phone: + 212 610 6365
elizabeth.holland@allenoverly.com

By: Anish R. Desai/
Anish R. Desai (Reg. No. 73,760)
Lead Counsel for Petitioner
Weil, Gotshal & Manges LLP
767 Fifth Avenue
New York, NY 10153
T: 212-310-8730
anish.desai@weil.com

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.